Yixuan Wang
Lecturer, Pharmacist-in-Charge
E-mail：yxwang111@suda.edu.cn
Biography
Yixuan Wang holds a Ph.D. in Pharmacology from Nanjing University and currently serves as a Lecturer and Pharmacist-in-Charge. Her research focuses on anti-inflammatory immunopharmacology and antitumor pharmacology. She leads three research grants: the Young Scientists Fund of the National Natural Science Foundation of China (NSFC), the Youth Program of the Natural Science Foundation of Jiangsu Province, and a grant from the Suzhou Municipal Science and Technology Bureau. She has published multiple articles in prestigious pharmacological journals, including Oncogene, Br J Pharmacol, and Acta Pharmacol Sin.
Select Publications (* represents corresponding author)
1.Yixuan Wang, Ying Huang, Liwei Wang, Zhixiu Chen, Lin Zhou, Xiang Feng, Guoyu Li, Jiawen Yang, Rui Chen, Qiang Xu, Yan Shen. TP53INP2 promotes mitophagic degradation of YAP to impede dedifferentiated liposarcoma development. Oncogene. 44(25):2054-2063 (2025).
2.Yixuan Wang, Liwei Wang, Ying Huang, Lin Zhou, Guoyu Li, Jia-wen Yang, Xue feng Wu, Jing cai Cheng, Qiang Xu, Yan Shen. Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73. Acta Pharmacol Sin. 46(6):1722-1732 (2025).
3. Yixuan Wang, Jian Gao, Ying Yu, Lin Zhou, Miao Wang, Wenwen Xue, Bo Liu, Xudong Wu, Xuefeng Wu, Huiyuan Gao, Yan Shen, Qiang Xu. A plant-derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy. Br J Pharmacol. 180(2):194-213 (2023).
4. Jian Gao# , Zhixiu Chen# , Yixuan Wang# , Lele Guo , Minmin Fan , Lin Zhou , Liwei Wang , Ying Huang , Yang Sun , Wenjie Guo , Yan Shen , Qiang Xu. Tumoral IL-10-activated SHP2 in macrophages promotes mammary carcinoma progression. Fundamental Research. (2024).
5. Ahmed Elgehama#, Yixuan Wang#, Ying Yu, Lin Zhou, Zhixiu Chen, Liwei Wang, Lijun Sun, Jian Gao, Biao Yu, Yan Shen, Qiang Xu. Targeting the PTP1B-Bcr-Abl1 interaction for the degradation of T315I mutant Bcr-Abl1 in chronic myeloid leukemia. Cancer Sci. 114(1):247-258 (2023).
6. Xue W, Li X, Li W, Wang Y, Jiang C, Zhou L, Gao J, Yu Y, Shen Y, Xu Q. Intracellular CYTL1, a novel tumor suppressor, stabilizes NDUFV1 to inhibit metabolic reprogramming in breast cancer. Signal Transduct Target Ther. 4;7(1):35 (2022).
